Global Information
회사소개 | 문의 | 비교리스트

세계의 약가 및 의료비 상환 시장

Pharmaceutical Pricing and Reimbursement: Global Markets

리서치사 BCC Research
발행일 2020년 07월 상품 코드 948545
페이지 정보 영문 164 Pages
가격
US $ 4,950 ₩ 5,931,000 PDF (Single User License)
US $ 5,940 ₩ 7,117,000 PDF (2-5 Users)
US $ 7,128 ₩ 8,540,000 PDF (Site License)
US $ 8,554 ₩ 10,249,000 PDF (Enterprise License)


세계의 약가 및 의료비 상환 시장 Pharmaceutical Pricing and Reimbursement: Global Markets
발행일 : 2020년 07월 페이지 정보 : 영문 164 Pages

세계의 의약품 시장 규모는 2019년 1조 580억 달러에서 2024년까지 1조 5,200억 달러에 달할 것으로 예측되며, 2019-2024년간 7.5%의 CAGR이 전망됩니다.

세계 의약품 시장의 약가 및 의료비 상환에 대해 조사했으며, 과거 10년간 세계 의약품 시장의 의료 제도 개혁과 규제, 그것들이 업계 M&A, 벤처 캐피털리스트 투자에 미치는 영향 등의 분석, 미국·유럽의 약가 설정·의료비 상환 정책·프로세스 및 제네릭 의약품, 바이오시밀러, 시판약(OTC), 소분자, 생물학적 제제에 대한 의약품 투자 방법 리뷰 등을 제공합니다.

제1장 서론

  • 연구 목표와 목적
  • 조사 이유
  • 보고서 범위
  • 정보 출처
  • 조사 방법
  • 지역 내역
  • 애널리스트 경력
  • BCC 맞춤형 조사
  • BCC Research 관련 보고서

제2장 요약과 하이라이트

제3장 세계의 헬스케어 지출, 법률 및 가격 설정 메커니즘

  • 세계의 헬스케어 비용
  • COVID 전 예측
  • COVID 후 예측
  • COVID-19에 대한 급성기 의료 대응
  • 저비용 디지털 서비스 확대
  • COVID-19용 연구개발 자금
  • 의약품 지출
  • 북미
  • 유럽
  • 일본
  • BRIC
  • 2020년 1분기 의약품 매출에 대한 COVID-19의 영향
  • 합병과 인수(M&A)
  • 2019년 이전 M&A 활동
  • 2019년 M&A 활동
  • 2020년 1분기 M&A 활동
  • 헬스케어 개혁
  • 프랑스
  • 독일
  • 이탈리아
  • 스페인
  • 영국
  • 미국
  • 의약품 규제
  • 프랑스
  • 독일
  • 이탈리아
  • 스페인
  • 영국
  • 미국
  • 헬스케어에 대한 COVID-19의 급성적 영향
  • 프랑스
  • 독일
  • 이탈리아
  • 스페인
  • 영국
  • 미국

제4장 가격 설정 전략

  • 서론
  • 의약품 비용 상승의 주요 이유
  • 오래된, 저비용 의약품에서 새로운, 보다 고가 의약품으로의 치환
  • 의약품 사용 증가
  • 지금까지 치료제가 없었던 질환의 신약
  • 기존약의 가격 상승
  • 의약품 가격 설정 전략
  • 외부 가격 참조
  • 내부 참조 가격
  • 처방약 가격
  • 영국
  • 미국
  • 시판약(OTC) 가격
  • 유럽
  • 영국
  • 미국
  • 제네릭 의약품 가격
  • 영국
  • 미국
  • 희귀의약품 가격
  • 가치 기준 가격 설정(Value-Based Pricing)
  • 공개 입찰 초대와 조달
  • 기본협정(Framework Agreement)

제5장 의료비 상환 전략

  • 의약품 상환
  • 의료비 상환 승인
  • 의료비 상환 절차
  • 유럽
  • 영국
  • 미국
  • 병원 의료비 상환
  • 유럽
  • 영국
  • 미국
  • 환자 액세스 스킴
  • 재무 기반 스킴
  • 결과 기반 스킴
  • 의약품 스킴으로의 조기 액세스
  • 유럽
  • 영국
  • 미국
  • 처방 리스트
  • 유럽
  • 영국
  • 미국
  • 의료기술평가(HTA)
  • 유럽
  • 영국
  • 미국
  • 보건경제 및 성과연구(HEOR)의 가치
  • HEOR Top 10 동향

제6장 향후

  • 가치 기준 가격 설정 스킴 채용 확대
  • 세포·유전자 치료에 대한 투자 증가
  • 혁신적인 지불 모델
  • Brexit가 보다 명확하게
  • 약가를 둘러싼 정치적 논쟁
  • COVID-19에 대한 장기적인 대응은 불명확

제7장 참고 자료

KSM 20.07.31

List of Tables

  • Table 1 : Major Market Drivers of Global Healthcare Expenditures
  • Table 2 : Total Healthcare Expenditure in G20 Economies, 2018
  • Table 3 : Inpatient Care Average Length of Stay in All Hospitals, 2014
  • Table 4 : Steps Implemented to Access Diagnostics and Treatment Following the COVID-19 Pandemic
  • Table 5 : Steps Implemented to Boost and Optimize Healthcare Capacity
  • Table 6 : COVID-19 Vaccines under Development
  • Table 7 : COVID-19 Treatments under Development
  • Table 8 : Major Mergers and Acquisitions in the Global Pharmaceutical Market, 2019
  • Table 9 : Major M&A Deals in the Global Pharmaceutical Market, Q1 2020
  • Table 10 : Allowed Growth Rates, 2014-2018
  • Table 11 : Net Revenues Retained in the U.S. Pharmaceutical Market, by Type of Prescription Drug Participant, 2016
  • Table 12 : Pricing of Medicines in Europe
  • Table 13 : Using Market Forces to Price Generics in the U.K.
  • Table 14 : Pricing Policies for Biosimilars in Europe, as of April 2017
  • Table 15 : National Authorities in Charge of Market Authorization, Pricing and Reimbursement in the EU5 Countries
  • Table 16 : Federally Funded Health Insurance Programs in the U.S.
  • Table 17 : An Overview of Early Access Schemes
  • Table 18 : Example of a Five-Tier Formulary System in the U.S.
  • Table 19 : Acronyms Used in the Global Pharmaceutical Pricing and Reimbursement Market

List of Figures

  • Figure 1 : Projected Annual Growth in Global Healthcare Spending, 2020
  • Figure 2 : Global GDP Growth Forecast Comparison, February 2020 vs. May 2020
  • Figure 3 : Overview of Coronavirus Impact Index, by Industry
  • Figure 4 : Potential Initial Impact of Partial or Complete Shutdowns on Activity in the G7 Economies
  • Figure 5 : Schematic Diagram of Global Healthcare Spend to Increase, 2020
  • Figure 6 : Trends in Global Pharmaceuticals Sales, by Market Segment, 2018-2024
  • Figure 7 : Projected Annual Growth Forecast in Global Pharmaceutical Market, by Region Group, 2018-2022
  • Figure 8 : Market Shares of Generic Medicine Sales in Selected European Countries, as of 2016
  • Figure 9 : Cumulative Pharmaceutical M&A Spending Comparison, 2019 vs. 2018
  • Figure 10 : Healthcare Reforms in Germany
  • Figure 11 : Worldwide Confirmed Cases and Number of Fatalities from COVID-19, as Reported by WHO, as of May 24, 2020
  • Figure 12 : Regional Confirmed Cases and Number of Fatalities from COVID-19, as Reported by WHO, as of May 24, 2020
  • Figure 13 : European Countries Where External Reference Pricing is Used
  • Figure 14 : Overview of Countries that Refer to the U.K.
  • Figure 15 : European Countries Where Internal Reference Pricing is Used
  • Figure 16 : NHS Spending on Prescription Pharmaceuticals, 2010-2018
  • Figure 17 : Pharmaceutical Pricing Process in the U.S.
  • Figure 18 : Countries Using Generic Prices in Europe
  • Figure 19 : Share of Generic Drug Sales (by Value and Volume) Across the OECD Nations, 2014
  • Figure 20 : Comparing Prices of Biosimilars and Branded Products
  • Figure 21 : U.S., EU and Japan Orphan Designations per Year and Cumulative, 1983-2016
  • Figure 22 : Top 100 Orphan Drug Costs per Patient per Year in the U.S., 2012-2016
  • Figure 23 : Value-Based Pricing Process in the U.K.
  • Figure 24 : Overview of Pharmaceutical Tendering Process
  • Figure 25 : Overview of the Application of Reimbursement Schemes in Europe
  • Figure 26 : Organization of the U.S. Healthcare System
  • Figure 27 : U.S. Healthcare Expenditures as a Share of GDP, by Source of Funds, 1987-2018
  • Figure 28 : Organization of the Healthcare System in England
  • Figure 29 : Evolution of PAS England, 2007-2015
  • Figure 30 : PAS Approval Process (Simplified Version)
  • Figure 31 : Pathways for Accessing an Orphan Therapy in the EU
  • Figure 32 : Three-Stage EAMS Process in the U.K.
  • Figure 33 : Types of Reimbursement Lists Used in the Outpatient Sector Europe
  • Figure 34 : Process of Identifying if an Item Can be Prescribed on the NHS
  • Figure 35 : Two Simplified Examples of HTA Utilization in Europe
  • Figure 36 : Tools and Disciplines Involved HEOR Analysis
  • Figure 37 : Elements of Value-Based Pricing
  • Figure 38 : Global Cell and Gene Therapy Market, 2018 vs. 2024
  • Figure 39 : Innovative Payment Models for Cell and Gene Therapies
  • Figure 40 : Four Waves of COVID-19 on Healthcare

Highlights:

The global pharmaceuticals market was valued at $1,058 billion in 2019 and should reach $1,520 billion by 2024 with a compound annual growth rate (CAGR) of 7.5% from 2019 to 2024.

Report Scope:

This new report on pricing and reimbursement in a global market provides a brief overview on the pharmaceutical markets, healthcare reforms and regulations across the globe over the last decade and how this has impacted mergers and acquisitions and venture capitalist investment in the sector. It reviews pricing and reimbursement policies and processes in the U.S. and Europe and the ways in which pharmaceutical investment in generics, biosimilars, over the counter (OTC), small molecule and biological agents; and the shift toward more innovative medicines such as cell and gene therapies may change future treatment paradigms and future pricing and reimbursement policies.

Report Includes:

  • An overview of the global markets for pharmaceuticals, specifically healthcare legislation and regulation, pricing mechanisms, and reimbursement procedures
  • Analyses of the global market trends, with data corresponding to market size for 2014-2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Information on the current price and reimbursement landscape, benchmarking statics, and future development opportunities in the pharma industry
  • Case studies of different price and reimbursement strategies for prescription drugs, orphan drugs, generics, over-the-counter products, and value-based pricing
  • Discussion on the impact of COVID-19 on pharmaceutical sales in Q1 2020 and overall healthcare marketplace
  • Insight into the greater adoption of value-based pricing schemes, with emphasis on the innovative payment models, increased investment in cell and gene therapies, and long-term response to COVID-19

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Global Healthcare Expenditures, Legislation and Pricing Mechanisms

  • Global Healthcare Costs
  • Forecasts Pre-COVID
  • Forecasts Post-COVID
  • Acute Healthcare Response to COVID-19
  • Expansion of Low-Cost Digital Services
  • Funding for COVID-19 Research and Development
  • Drug Expenditures
  • North America
  • Europe
  • Japan
  • BRIC Economies
  • Impact of COVID-19 on Pharmaceutical Sales in Q1 2020
  • Mergers and Acquisitions (M&A)
  • M&A Activity Pre-2019
  • M&A Activity in 2019
  • M&A Activity in Q1 2020
  • Healthcare Reforms
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • United States
  • Pharmaceutical Regulation
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • United States
  • Acute Impact of COVID-19 on Healthcare
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • United States

Chapter 4 Pricing Strategies

  • Introduction
  • Primary Reasons for the Rise in the Cost of Pharmaceuticals
  • Replacement of Older, Lower-Cost Drugs by Newer, Higher Priced Drugs
  • Increased Use of Drugs
  • New Drugs for Diseases for Which No Treatment Was Previously Available
  • Increases in the Prices of Existing Medicines
  • Pharmaceutical Pricing Strategies
  • External Price Referencing
  • Internal Referencing Pricing
  • Prescription Drug Pricing
  • United Kingdom
  • United States
  • Over-the-Counter (OTC) Drug Pricing
  • Europe
  • United Kingdom
  • United States
  • Generic Drug Pricing
  • United Kingdom
  • United States
  • Orphan Drug Pricing
  • Value-Based Pricing
  • Open Tender Invitations and Procurement
  • Framework Agreements

Chapter 5 Reimbursement Strategies

  • Pharmaceutical Reimbursement
  • Admission to Reimbursement
  • Reimbursement Procedure
  • Europe
  • United Kingdom
  • United States
  • Hospital Reimbursement
  • Europe
  • United Kingdom
  • United States
  • Patient Access Schemes
  • Financially Based Schemes
  • Outcome-Based Schemes
  • Early Access to Medicines Schemes
  • Europe
  • United Kingdom
  • United States
  • Formulary Lists
  • Europe
  • United Kingdom
  • United States
  • Health Technology Assessments (HTA)
  • Europe
  • United Kingdom
  • United States
  • The Value of Health Economics and Outcome Research (HEOR)
  • Top 10 HEOR Trends

Chapter 6 The Future

  • Greater Adoption of Value-Based Pricing Schemes
  • Increased Investment in Cell and Gene Therapies
  • Innovative Payment Models
  • Greater Clarity on Brexit
  • Political Wrangling Over Drug Prices
  • Long-term Response to COVID-19 Undefined

Chapter 7 References

Back to Top
전화 문의
F A Q